Sefitude (Quietude) Húðuð tafla 445 mg Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

sefitude (quietude) húðuð tafla 445 mg

florealis ehf. - valerian root dry extract (3-6:1), ethanol 70 %(v/v) - húðuð tafla - 445 mg

Qlaira Filmuhúðuð tafla Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

qlaira filmuhúðuð tafla

bayer ab - estradiolum valerat; dienogestum inn; estradiolum valerat - filmuhúðuð tafla

Betnovat Húðlausn 1 mg/ml Ísland - íslenska - LYFJASTOFNUN (Icelandic Medicines Agency)

betnovat húðlausn 1 mg/ml

glaxosmithkline pharma a/s - betamethasonum valerat - húðlausn - 1 mg/ml

Ronapreve Evrópusambandið - íslenska - EMA (European Medicines Agency)

ronapreve

roche registration gmbh  - casirivimab, imdevimab - covid-19 virus infection - Ónæmiskerfið sera og mótefni, - ronapreve is indicated for:treatment of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg who do not require supplemental oxygen and who are at increased risk of progressing to severe covid-19 (see section 4. prevention of covid-19 in adults and adolescents aged 12 years and older weighing at least 40 kg (see section 4. the use of ronapreve should take into account information on the activity of ronapreve against viral variants of concern. sjá kafla 4. 4 og 5.

Nuvaxovid Evrópusambandið - íslenska - EMA (European Medicines Agency)

nuvaxovid

novavax cz, a.s. - sars cov-2 (original) recombinant spike protein, sars-cov-2 (omicron xbb.1.5) recombinant spike protein - covid-19 virus infection - covid-19 vaccines - nuvaxovid is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur. nuvaxovid xbb. 5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 12 years of age and older. notkun þetta bóluefni ætti að vera í samræmi við opinbera tillögur.